How do you monitor and manage the risks and uncertainties of patient access schemes?
Patient access schemes (PAS) are agreements between pharmaceutical companies and payers that aim to improve the affordability and value of new medicines. They can take various forms, such as discounts, rebates, outcomes-based payments, or free doses. However, PAS also entail risks and uncertainties for both parties, such as operational costs, data collection challenges, ethical issues, or market dynamics. How do you monitor and manage these factors to ensure the success and sustainability of your PAS? Here are some tips to help you.